SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biochem Pharma (BCHE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Childs who wrote (207)1/8/1998 8:06:00 AM
From: biodoc   of 783
 
Once again, Viracept is a protease inhibitor while 3-TC is a reverse transcriptase inhibitor. Current therapy for HIV consists of a three (at least) drug combination with one protease inhibitor and two reverse transcriptase inhibitors. Viracept and 3-TC are NOT competing drugs. Neither drug has any place as a single agent. Most but not all combinations include 3-TC. Of the protease inhibitors, Viracept is gaining market share over Merck's drug, Crixivan, but not at the expense of 3-TC (since they are not the same class of drug).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News